Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014)

Zevra Therapeutics' (ZVRA) quarterly Preferred Stock Liabilities came in at $24.2 million in Q4 2014.

Zevra Therapeutics (ZVRA) Preferred Stock Liabilities (2014) Analysis & Trends

Zevra Therapeutics (ZVRA) has 1 years of Preferred Stock Liabilities data on file, last reported at $24.2 million in Q4 2014.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $24.2 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $24.2 million (changed N/A YoY) and the FY2014 annual result came in at $24.2 million, up 30.51% from the prior year.
Preferred Stock Liabilities steadied at $24.2 million in Q4 2014.
In the past five years, Preferred Stock Liabilities ranged from a high of $24.2 million in Q4 2014 to a low of $24.2 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Zevra Therapeutics	671.75 Mn	450.18 Mn	38.18 Mn	-

Download Data

Date	Value
Dec 31, 2014	24.21 Mn